Question ID: WS-56
Submitted by: Masoud Manjili
February 11, 2011
Does inflammatory immune response play any role in determining progression of DCIS to invasive breast cancer? Background: 55-75% of DCIS patients overexpress HER-2/neu in their lesions and are at a greater risk of developing invasive breast cancer. On the other hand, 75% of patients with invasive breast cancer do not overexpress HER-2/neu in their tumors. In addition, several reports suggest that T cell responses, IFN-g in particular, may simultaneously induce apoptosis and HER-2/neu antigen loss in the tumors even in patients with DCIS. Feasibility: Gene array technology as well as IHC are available to determine inflammatory types of the immune response in DCIS lesions. Implications of success: If we can identify distinct types of the immune response signature that can favor patients and those that may induce epigenetic changes in the tumors (tumor antigen loss) and result in tumor escape and recurrence, we may be able to develop a highly tailored immunotherapy for patients with patients with DCIS and breast cancer.
| This question has not yet been evaluated by users |
Comments
